Eyal C Attar
Overview
Explore the profile of Eyal C Attar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2540
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amrein P, Preffer F, Fell G, Attar E, Narayan R, Blonquist T, et al.
Leuk Lymphoma
. 2025 Mar;
:1-11.
PMID: 40070233
Outcome for acute myeloid leukemia (AML) patients aged >60 years is poor. Targeting the proteasome in AML is attractive, since leukemia stem cells demonstrate sensitivity to proteasome inhibition in preclinical...
2.
Garcia-Manero G, Goldberg A, Winer E, Altman J, Fathi A, Odenike O, et al.
Lancet Haematol
. 2023 Mar;
10(4):e272-e283.
PMID: 36990622
Background: TP53-mutated acute myeloid leukaemia is associated with poor outcomes. Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator. We aimed to evaluate the combination of eprenetapopt and venetoclax with or...
3.
Mishra A, Tamari R, DeZern A, Byrne M, Gooptu M, Chen Y, et al.
J Clin Oncol
. 2022 Jul;
40(34):3985-3993.
PMID: 35816664
Purpose: Outcomes are poor in -mutant (m) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant (HCT). Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator....
4.
Sallman D, DeZern A, Garcia-Manero G, Steensma D, Roboz G, Sekeres M, et al.
J Clin Oncol
. 2021 Jan;
39(14):1584-1594.
PMID: 33449813
Purpose: Approximately 20% of patients with -mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions...
5.
Choe S, Wang H, DiNardo C, Stein E, de Botton S, Roboz G, et al.
Blood Adv
. 2020 May;
4(9):1894-1905.
PMID: 32380538
Isocitrate dehydrogenase (IDH) 1 and 2 mutations result in overproduction of D-2-hydroxyglutarate (2-HG) and impaired cellular differentiation. Ivosidenib, a targeted mutant IDH1 (mIDH1) enzyme inhibitor, can restore normal differentiation and...
6.
Fan B, Dai D, DiNardo C, Stein E, de Botton S, Attar E, et al.
Cancer Chemother Pharmacol
. 2020 Apr;
85(5):959-968.
PMID: 32296873
Purpose: Isocitrate dehydrogenase (IDH) mutations lead to formation of the oncometabolite 2-hydroxyglutarate (2-HG), which is elevated in several solid and liquid tumors. Ivosidenib (AG-120) is a targeted, potent, oral inhibitor...
7.
Stein E, Fathi A, DiNardo C, Pollyea D, Roboz G, Collins R, et al.
Lancet Haematol
. 2020 Mar;
7(4):e309-e319.
PMID: 32145771
Background: Mutations in isocitrate dehydrogenase-2 (IDH2) occur in around 5% of patients with myelodysplastic syndromes. Neomorphic activity of mutant IDH2 proteins results in hypermethylation of DNA and histones, leading to...
8.
Roboz G, DiNardo C, Stein E, de Botton S, Mims A, Prince G, et al.
Blood
. 2019 Dec;
135(7):463-471.
PMID: 31841594
Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme. From a phase 1 study...
9.
Ustun C, Le-Rademacher J, Wang H, Othus M, Sun Z, Major B, et al.
Leukemia
. 2019 May;
33(11):2599-2609.
PMID: 31073153
The preferred post-remission therapy for older patients with acute myeloid leukemia (AML) in first complete remission (CR1) remains uncertain. In this retrospective, multicenter study, we compared the outcomes for older...
10.
Pollyea D, Tallman M, de Botton S, Kantarjian H, Collins R, Stein A, et al.
Leukemia
. 2019 Apr;
33(11):2575-2584.
PMID: 30967620
Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12-15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2)...